查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1950538

小分子CDMO服务市场依服务类型、分子类型、研发阶段、生产规模、治疗领域及客户类型划分，全球预测，2026-2032年

Small Molecules CDMO Services Market by Service Type, Molecule Type, Development Stage, Production Scale, Therapeutic Area, Customer Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，小分子 CDMO 服务市场价值将达到 91.5 亿美元，到 2026 年将成长至 101.5 亿美元，到 2032 年将达到 212.5 亿美元，复合年增长率为 12.79%。

关键市场统计数据
基准年 2025 91.5亿美元
预计年份：2026年 101.5亿美元
预测年份 2032 212.5亿美元
复合年增长率 (%) 12.79%

小分子CDMO产业的简明框架：强调对综合服务的需求、与研发阶段的契合度以及随着规模扩大而出现的营运重点。

小分子药物合约研发生产机构（CDMO）产业正处于关键的转折点，各公司都在寻求专业的合作伙伴，以加速药物研发进程并优化成本效益。由于申办方公司将速度、品质和监管合规性置于商品价格之上，因此对涵盖分析服务、原料药生产、製剂和包装以及全面製程开发的端到端能力的需求日益增长。製程开发本身也在不断发展，将製程优化、合成路线优化、通路筛检和技术转移整合起来，成为科学洞见与生产实用性的关键交会点。

技术进步、监管收紧和赞助商策略转变如何重塑CDMO在各个研发阶段的竞争与伙伴关係模式

随着技术、监管和商业性因素的融合，CDMO（合约研发生产机构）产业近期发生的变革性变化正在重新定义竞争优势。连续生产和模组化设施设计正从概念验证迈向商业性化应用阶段，从而实现更快的製程优化和更灵活的规模化生产。这些技术进步与先进分析方法和数位化工具的广泛应用相辅相成，提高了途径筛检的通量，加速了催化剂和试剂的分析，并增强了技术转移过程中的可预测性。因此，那些将高品质的实验室科学与可扩展的工程方法相结合的公司正在取代那些拥有单一模式生产优化资产的传统供应商。

分析2025年关税环境以及关税压力将如何加速近岸外包、区域产能扩张与供应链韧性策略

2025年高关税的实施为支持小分子药物研发和生产的全球供应链带来了新的复杂性。关税带来的成本压力迫使申办方和服务供应商重新评估其筹资策略，优先考虑区域供应安全，并加快关键原料药中间体和重要原料的近岸外包。为此，一些机构正在重新设计其采购框架，以降低跨境关税风险，同时确保其临床和商业项目的供应连续性。

深度細項分析表明，服务类型、开发阶段、治疗领域、客户画像和规模如何共同决定CDMO的产品设计和伙伴关係。

以细分市场为重点的策略性洞察揭示了服务类型、研发阶段、治疗领域、客户画像和规模如何影响整个CDMO产业的需求和产能要求。超越基础原料药生产，提供整合分析服务、製剂和包装以及全面製程开发的服务，能够降低药物发现到临床试验过渡阶段的风险，从而创造差异化价值。在製程开发方面，那些在製程优化和技术转移方面表现卓越，同时又具备涵盖催化剂、试剂和溶剂筛检的高通量路线筛检能力的供应商，对于希望缩短研发週期并减少后期意外问题的申办方而言，尤其有价值。

管理体制、人才供应和物流基础设施的区域差异会影响CDMO产能分配和赞助商筹资策略。

受法规结构、人才库和物流基础设施差异的影响，区域趋势正在重塑赞助商的投资和合约研发生产机构（CDMO）的产能分配。在美洲，成熟的科研生态系统和与主要赞助商的接近性，使得能够支持从分析方法开发到商业化生产全流程的综合服务供应商更具优势。该地区重视与国内监管机构的协调一致，并受益于成熟的合约结构，从而能够建立长期的战略合作伙伴关係。

对领先的CDMO企业差异化因素进行深入分析，重点关注其能力深度、策略伙伴关係以及以品质主导的商业性敏捷性。

CDMO产业的竞争格局取决于能力的广度、技术深度和商业性弹性。领先的供应商透过投资先进的分析平台、高通量路线筛检能力以及在复杂製程优化和技术转移方面累积的成熟经验来脱颖而出。这些能力有助于在规模化生产过程中更快地解决问题，并减少与监管机构沟通和返工所需的时间。能够将分析服务无缝整合到其开发流程中的公司可以提供更可靠的杂质控制策略和稳定性数据，这对于监管申报至关重要。

为CDMO和赞助公司经营团队的实用策略倡议，旨在加速能力整合、提升区域韧性，并实现从研发到生产的一体化工作流程。

产业领导者必须采取果断行动，透过将产能投资与专案方的优先事项和监管预期相一致，将市场复杂性转化为竞争优势。投资于模组化设施设计和灵活的生产线，以促进从微型和中试规模运营到商业化生产的快速过渡，缩短资本前置作业时间，并提高对专案需求波动的应对力。在研发生命週期的早期阶段优先整合分析服务，以确保将杂质分析、分析方法验证和稳定性测试纳入製程开发和生产路线优化工作中。

为了确保分析的严谨性，我们采用了一种高度透明且可重复的调查方法，结合了初步访谈、技术文件审查和多方面的检验。

本分析所依据的研究采用了三角验证法，结合了初步访谈、技术文献综述和对产业实务的独立检验，以建构强有力的证据基础。初步研究包括对发起公司和服务供应商的高级技术、法规和商业管理人员进行结构化访谈，重点关注营运流程、技术转移经验和采购决策标准。这些定性见解辅以已发布的法规指南和技术文献的审查，以确保与当前法规要求以及製程开发和分析检验方面的最佳实践保持一致。

结论强调了未来CDMO领导地位将取决于综合能力、区域韧性以及技术和营运方面的关键要素。

总而言之，小分子CDMO领域正朝着以科学主导的一体化伙伴关係发展，这种合作关係建立在灵活的生产能力、先进的分析整合以及区域供应链韧性之上。申办方越来越注重选择，他们会评估那些能够证明其具备成熟的製程优化能力、能够对催化剂、试剂和溶剂等变数进行高通量合成路线筛检以及可靠的技术转移通讯协定。这些能力贯穿整个研发过程，从临床前到I期、II期、III期以及商业化项目，并且必须适用于包括肿瘤、感染疾病、心血管疾病和中枢神经系统（CNS）疾病在内的各个治疗领域。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 小分子CDMO服务市场（依服务类型划分）

  • 製程开发
    • 路线规划与可行性研究
    • 流程优化
    • 规模化和技术转移
  • 客製合成
    • 基础模组和中间模组
    • 参考标准和杂质
    • 高活性物质
  • 符合现行良好生产规范 (CGMP) 的生产
    • 临床生产
    • 商业生产
  • 配方开发
    • 预配方测试
    • 固态口服剂型
    • 注射剂
  • 分析和品质保证服务
    • 方法开发与验证
    • 稳定性测试
    • 运输和进程内测试
    • 表征和结构解析
  • 包装和最终剂型
    • 初级包装
    • 二级包装
  • 监管和支援服务
    • CMC文檔支持
    • 监理备案支持
    • 验证和资格确认服务

9. 按分子类型分類的小分子CDMO服务市场

  • 活性药物成分
    • 新化学物质
    • 学名药成分
    • 高活性药物原料药
    • 管制物质
  • 中高级
    • 初级中等水平
    • 中后期
  • 主要起始原料
  • 杂质和参考标准
    • 工艺杂质
    • 分解产物
    • 分析用标准物质

10. 小分子CDMO服务市场依研发阶段划分

  • 药物发现与早期开发
  • 非临床试验
  • 临床
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 註册与验证
  • 商业的

11. 按生产规模分類的小分子CDMO服务市场

  • 实验室规模
  • 中试规模
  • 临床量表
  • 商业规模
    • 小规模商业生产
    • 大规模商业生产

12. 小分子CDMO服务市场（依治疗领域划分）

  • 肿瘤学
  • 循环系统
  • 中枢神经系统
  • 感染疾病
  • 代谢/内分泌
  • 呼吸系统
  • 消化器官系统
  • 自体免疫疾病与发炎性疾病
  • 皮肤科

13. 按客户类型分類的小分子CDMO服务市场

  • 大型製药公司
  • 中型製药公司
  • 小规模和新兴製药公司
  • 生技公司
  • 学名药生产商
  • 虚拟专业製药公司
  • 学术和研究机构

14. 小分子CDMO服务市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

15. 小分子CDMO服务市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各国小分子CDMO服务市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国小分子CDMO服务市场

18. 中国：小分子CDMO服务市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aenova Holding GmbH
  • Akums Drugs & Pharmaceuticals Ltd.
  • Almac Group Ltd.
  • Apeloa Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Ltd.
  • Bachem Holding AG
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Curia Global, Inc.
  • Divi's Laboratories Ltd.
  • EuroAPI
  • Evonik Industries AG
  • Fujifilm Diosynth Biotechnologies
  • Hovione Ltd.
  • Lonza Group AG
  • PCI Pharma Services
  • Piramal Pharma Solutions
  • Porton Pharma Solutions Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • Simtra BioPharma Solutions
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4F7A6D4FD8C9

The Small Molecules CDMO Services Market was valued at USD 9.15 billion in 2025 and is projected to grow to USD 10.15 billion in 2026, with a CAGR of 12.79%, reaching USD 21.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.15 billion
Estimated Year [2026] USD 10.15 billion
Forecast Year [2032] USD 21.25 billion
CAGR (%) 12.79%

A concise framing of the small molecules CDMO sector that highlights integrated service demand, development-stage alignment, and scale-driven operational priorities

The small molecules contract development and manufacturing organization (CDMO) landscape is at a pivotal juncture as companies seek specialized partners to accelerate translational pipelines and optimize cost-efficiency. Demand for end-to-end capabilities that span analytical services, API manufacturing, formulation and packaging, and comprehensive process development has increased as sponsors prioritize speed, quality, and regulatory robustness over commodity pricing. Process development itself now integrates process optimization, route optimization, route screening, and technology transfer as critical touchpoints where scientific insight and manufacturing pragmatism intersect.

Sponsors are engaging CDMOs across the full development continuum, from preclinical research through Phase I, Phase II, Phase III, and commercial stage operations, reflecting a strategic shift toward long-term external partnerships. Therapeutic focus areas such as oncology, infectious diseases, cardiovascular, and central nervous system programs exert differentiated demands on analytical methodologies, impurity profiling, and scale-up strategies. Customer types range from large pharmaceutical enterprises to mid-sized biopharma and small biotech firms, each bringing distinct procurement models, quality expectations, and risk appetites. Scale considerations-spanning micro scale workflows, pilot scale runs, and full commercial scale production-further shape the technical architecture and capital intensity of CDMO offerings.

As the industry converges on integrated services, providers that can demonstrate robust process transfer capabilities, high-throughput route screening including catalytic reagent and solvent screening, and validated analytical platforms will be positioned to win multi-year partnerships. This introduction sets the scene for deeper analysis of transformative shifts, tariff impacts, segmentation nuance, and region-specific dynamics that influence strategic sourcing and operational resilience.

How technological advancement, regulatory tightening, and evolving sponsor strategies are reshaping CDMO competitiveness and partnership models across development stages

Recent transformative shifts are redefining competitive advantage in the CDMO sector as technological, regulatory, and commercial forces converge. Continuous manufacturing and modular facility designs have progressed from proof-of-concept to commercial execution, enabling faster process optimization and more flexible scale transitions. These technological advances are complemented by broader adoption of advanced analytics and digital tools that enhance route screening throughput, accelerate catalyst and reagent profiling, and improve predictability during technology transfer. Consequently, firms that marry high-quality laboratory science with scalable engineering practices are displacing legacy providers whose assets are optimized for single-mode production.

Regulatory expectations have evolved in parallel, with agencies emphasizing enhanced impurity characterization, control strategy documentation, and lifecycle management. This raises the bar for analytical services, compelling CDMOs to integrate robust method development and validation earlier in the development stage continuum. Sponsors increasingly seek partners capable of supporting programs from preclinical through commercial stages, with clear handoffs across Phase I to Phase III activities and seamless scale-up from micro and pilot scales to commercial manufacture.

Strategic sourcing patterns have also shifted. Large pharma often pursues strategic alliances and co-development models, mid-sized biopharma favors flexible capacity arrangements and technical support, while small biotech prioritizes speed and technical risk reduction through targeted process development services. These shifts are shaping a competitive landscape where specialization, agility, and demonstrable quality systems determine market leadership. The cumulative effect is a sector moving toward integrated, science-driven partnerships underpinned by modern manufacturing paradigms and strengthened regulatory alignment.

An analysis of the 2025 tariff environment and how duty-driven pressures are accelerating nearshoring, regional capacity expansion, and supply chain resilience strategies

The introduction of elevated tariffs in 2025 has introduced a new layer of complexity for global supply chains serving small molecule development and manufacturing. Tariff-driven cost pressures are prompting sponsors and service providers to re-evaluate sourcing strategies, prioritize regional supply security, and accelerate nearshoring of critical API intermediates and key raw materials. In response, some organizations are redesigning procurement frameworks to reduce exposure to cross-border duties and to maintain continuity of supply for clinical and commercial programs.

Operationally, tariffs increase the incentive to localize certain manufacturing steps that are sensitive to logistics and cost variability, particularly final API synthesis and formulation work where transport of hazardous intermediates raises both regulatory scrutiny and landed cost. This has led to strategic investments in regional capacity expansions and selective reshoring initiatives that target micro and pilot scale activities as a precursor to larger commercial commitments. At the same time, process development activities-such as route optimization, catalytic and reagent screening, and technology transfer-are being concentrated closer to core manufacturing hubs to streamline handoffs and reduce cross-border procedural risk.

Tariffs have also altered commercial negotiations and contract structures, with longer-term agreements and price adjustments becoming more common as a hedge against future duty changes. Sponsors are increasingly assessing total landed cost and supply chain resilience, rather than focusing solely on unit production costs, when selecting CDMO partners. These dynamics underscore the importance of flexible manufacturing networks and strengthened regional capabilities to mitigate the practical impacts of tariff regimes on program timelines and regulatory submissions.

Deep segmentation insights showing how service type, development stage, therapeutic focus, customer profile, and scale collectively dictate CDMO offering design and partnerships

Segment-focused strategic insights reveal how service type, development stage, therapeutic focus, customer profile, and scale shape demand and capability requirements across the CDMO landscape. Service offerings that extend beyond basic API manufacturing into integrated analytical services, formulation and packaging, and comprehensive process development deliver differentiated value by de-risking transitions from discovery to clinic. Within process development, providers that excel at process optimization and technology transfer while maintaining high-throughput route screening capabilities-spanning catalytic, reagent, and solvent screening-are particularly valuable to sponsors seeking to shorten timelines and reduce late-stage surprises.

Development stage dynamics influence contracting models and technical priorities. Preclinical and Phase I engagements emphasize speed, material quality for early toxicology and first-in-human studies, and flexible micro scale or pilot scale operations. As programs advance into Phase II and Phase III, emphasis shifts toward scalability, reproducibility, and regulatory robustness, requiring CDMOs to demonstrate validated methods and reliable scale-up pathways. Therapeutic area requirements add another dimension: oncology programs often demand specialized impurity profiles and complex formulations, infectious disease efforts require rapid turnaround and supply flexibility, cardiovascular and CNS programs impose distinct physicochemical and stability challenges.

Customer segmentation further differentiates expectations. Large pharmaceutical sponsors often pursue strategic, long-term partnerships and co-development arrangements, mid-sized biopharma seeks flexible capacity with strong technical support, and small biotech prioritizes speed to clinic and risk mitigation through dedicated process development. Scale considerations-ranging from micro scale exploratory work to pilot and commercial scale manufacture-drive capital intensity, facility design, and quality system requirements. Taken together, these segmentation vectors form a matrix that CDMOs must navigate to align service architectures with sponsor priorities and therapeutic complexity.

How regional variation in regulatory regimes, talent availability, and logistics infrastructure is influencing CDMO capacity allocation and sponsor sourcing strategies

Regional dynamics are reshaping where sponsors invest and where CDMOs deploy capacity, driven by differences in regulatory frameworks, talent pools, and logistics infrastructure. In the Americas, established scientific ecosystems and proximity to large sponsors favor integrated service providers that can support end-to-end development from analytic method development through commercial scale production. This region emphasizes regulatory alignment with domestic agencies and benefits from mature contract structures that accommodate long-term strategic alliances.

Across Europe, the Middle East & Africa, regulatory stringency and access to skilled chemistry and manufacturing specialists create opportunities for high-precision process development and specialized pilot scale work. The region's diversity in regulatory expectations makes local expertise and robust technology transfer processes particularly important, while proximity to multiple markets supports flexible supply chains. In the Asia-Pacific region, rapid capacity expansion, cost-competitive manufacturing, and a growing skilled workforce make it an important hub for large-volume API manufacturing and formulation work, although sponsors increasingly demand transparent quality systems and traceable supply chains as a condition of partnership.

Taken together, these regional distinctions inform sourcing strategies and capital allocation. Sponsors seeking to reduce tariff exposure and logistic complexity are balancing capacity across these regions to combine speed, quality, and cost-effectiveness. For CDMOs, regional investment decisions must factor in local regulatory expectations, the availability of technical talent capable of advanced route screening and process optimization, and the need for robust quality systems that facilitate cross-border technology transfer and global registrations.

Insightful analysis of what differentiates leading CDMO companies, focusing on capability depth, strategic partnerships, and quality-driven commercial agility

Competitive positioning across the CDMO landscape is grounded in capability breadth, technical depth, and commercial agility. Leading providers differentiate themselves through investments in advanced analytical platforms, high-throughput route screening capabilities, and demonstrable expertise in complex process optimization and technology transfer. These capabilities enable faster troubleshooting during scale-up and reduce time spent on regulatory dialog and rework. Firms that integrate analytical services seamlessly into development workflows can offer more reliable impurity control strategies and stability data, which are critical during regulatory submissions.

Strategic partnerships and targeted capacity expansions are common moves among high-performing companies seeking to capture long-term programs. Collaboration models that combine sponsor scientific expertise with CDMO engineering and regulatory knowledge create co-development pathways that de-risk late-stage development. Additionally, companies that offer flexible scale options-spanning micro and pilot scale through commercial scale-attract a broader client base, from small biotech to large pharmaceutical firms. Investment in digitalization, data integrity, and advanced process control further separates leading providers by improving predictability during process transfers and by enabling continuous improvement across production campaigns.

Finally, top performers emphasize regulatory compliance and quality culture, recognizing that audits and supply continuity are decisive factors in partner selection. The ability to present validated methods, robust stability programs, and transparent supply chain traceability positions companies to win complex programs across therapeutic areas such as oncology and infectious diseases where regulatory scrutiny and supply demand are both high.

Actionable strategic moves for CDMO and sponsor executives to accelerate capability alignment, regional resilience, and integrated development-to-manufacturing workflows

Industry leaders must act decisively to convert market complexity into competitive advantage by aligning capability investments with sponsor priorities and regulatory expectations. Invest in modular facility designs and flexible manufacturing lines that facilitate rapid transitions from micro and pilot scale operations to commercial scale production, thereby reducing capital lead time and improving responsiveness to shifting program demands. Prioritize integration of analytical services early in the development lifecycle to ensure impurity profiling, method validation, and stability work are embedded within process development and route optimization efforts.

Strengthen regional footprints to mitigate tariff exposure and logistics risk while balancing cost and regulatory requirements. Establish cross-regional technology transfer playbooks and harmonized quality systems that reduce friction during handoffs and support global registrations. Forge strategic collaborations with sponsors that extend beyond transactional service delivery to co-development arrangements that align incentives around program milestones, knowledge transfer, and long-term supply commitments. Finally, invest in digital tools that enhance route screening throughput, capture process knowledge during optimization and technology transfer, and support predictive maintenance in manufacturing operations to reduce unplanned downtime and improve overall program predictability.

A transparent and replicable research methodology combining primary interviews, technical dossier reviews, and multi-source validation to ensure analytical rigor

The research underpinning this analysis combined triangulation of primary interviews, technical dossier reviews, and independent verification of industry practices to create a robust evidence base. Primary research included structured interviews with senior technical, regulatory, and commercial leaders across sponsors and service providers, focusing on operational workflows, technology transfer experiences, and procurement decision criteria. These qualitative insights were supplemented by reviews of public regulatory guidance and technical literature to ensure alignment with current agency expectations and best practices in process development and analytical validation.

Analytical rigor was applied through cross-validation of technical claims, facility capability checks, and a synthesis of case studies highlighting route screening approaches, catalytic and reagent selection strategies, and technology transfer outcomes. Data quality controls included multiple-source confirmation of stated capabilities, validation of process transfer timelines against documented milestones, and expert review panels to surface potential biases and ensure interpretive accuracy. The methodology prioritized transparency and replicability, documenting interview protocols, inclusion criteria for case studies, and the rationale for segmentation choices across service type, development stage, therapeutic area, customer type, and scale.

A clear concluding synthesis highlighting integrated capabilities, regional resilience, and the technical-operational axis that will determine future CDMO leadership

In summary, the small molecules CDMO sector is evolving toward integrated, science-driven partnerships underpinned by flexible manufacturing, advanced analytical integration, and regional supply resilience. Sponsors are increasingly selective, valuing providers that can demonstrate proven process optimization, high-throughput route screening capacity across catalytic, reagent, and solvent variables, and reliable technology transfer protocols. These capabilities are essential across the full development continuum from preclinical through Phase I, Phase II, Phase III, and commercial programs, and they must be adaptable across therapeutic areas including oncology, infectious diseases, cardiovascular, and CNS indications.

Regional strategies and tariff dynamics are accelerating shifts in capacity allocation, prompting localized investments and more sophisticated procurement frameworks that emphasize total landed cost and supply continuity. Companies that invest in modular facilities, harmonized quality systems, and integrated analytical platforms will be better positioned to capture long-term partnerships with large pharma, mid-sized biopharma, and small biotech clients. The conclusion is clear: technical excellence combined with operational agility and regional foresight will determine which providers lead the next phase of growth and which sponsors achieve the fastest, most reliable paths to clinic and market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Small Molecules CDMO Services Market, by Service Type

  • 8.1. Process Development
    • 8.1.1. Route Scouting And Feasibility
    • 8.1.2. Process Optimization
    • 8.1.3. Scale Up And Technology Transfer
  • 8.2. Custom Synthesis
    • 8.2.1. Building Blocks And Intermediates
    • 8.2.2. Reference Standards And Impurities
    • 8.2.3. High Potency Compounds
  • 8.3. CGMP Manufacturing
    • 8.3.1. Clinical Manufacturing
    • 8.3.2. Commercial Manufacturing
  • 8.4. Formulation Development
    • 8.4.1. Pre Formulation Studies
    • 8.4.2. Solid Oral Formulations
    • 8.4.3. Parenteral Formulations
  • 8.5. Analytical And Quality Services
    • 8.5.1. Method Development And Validation
    • 8.5.2. Stability Testing
    • 8.5.3. Release And In Process Testing
    • 8.5.4. Characterization And Structural Elucidation
  • 8.6. Packaging And Finished Dosage
    • 8.6.1. Primary Packaging
    • 8.6.2. Secondary Packaging
  • 8.7. Regulatory And Support Services
    • 8.7.1. CMC Documentation Support
    • 8.7.2. Regulatory Filing Support
    • 8.7.3. Validation And Qualification Services

9. Small Molecules CDMO Services Market, by Molecule Type

  • 9.1. Active Pharmaceutical Ingredients
    • 9.1.1. New Chemical Entities
    • 9.1.2. Generic APIs
    • 9.1.3. Highly Potent APIs
    • 9.1.4. Controlled Substances
  • 9.2. Advanced Intermediates
    • 9.2.1. Early Intermediates
    • 9.2.2. Late Stage Intermediates
  • 9.3. Key Starting Materials
  • 9.4. Impurities And Reference Standards
    • 9.4.1. Process Impurities
    • 9.4.2. Degradation Products
    • 9.4.3. Analytical Reference Standards

10. Small Molecules CDMO Services Market, by Development Stage

  • 10.1. Discovery And Early Development
  • 10.2. Preclinical
  • 10.3. Clinical
    • 10.3.1. Phase I
    • 10.3.2. Phase II
    • 10.3.3. Phase III
  • 10.4. Registration And Validation
  • 10.5. Commercial

11. Small Molecules CDMO Services Market, by Production Scale

  • 11.1. Laboratory Scale
  • 11.2. Pilot Scale
  • 11.3. Clinical Scale
  • 11.4. Commercial Scale
    • 11.4.1. Small Volume Commercial
    • 11.4.2. Large Volume Commercial

12. Small Molecules CDMO Services Market, by Therapeutic Area

  • 12.1. Oncology
  • 12.2. Cardiovascular
  • 12.3. Central Nervous System
  • 12.4. Infectious Diseases
  • 12.5. Metabolic And Endocrine
  • 12.6. Respiratory
  • 12.7. Gastrointestinal
  • 12.8. Autoimmune And Inflammatory
  • 12.9. Dermatology

13. Small Molecules CDMO Services Market, by Customer Type

  • 13.1. Large Pharmaceutical Companies
  • 13.2. Mid Size Pharmaceutical Companies
  • 13.3. Small And Emerging Pharmaceutical Companies
  • 13.4. Biotechnology Companies
  • 13.5. Generic Drug Manufacturers
  • 13.6. Virtual And Specialty Pharma
  • 13.7. Academic And Research Institutions

14. Small Molecules CDMO Services Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Small Molecules CDMO Services Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Small Molecules CDMO Services Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Small Molecules CDMO Services Market

18. China Small Molecules CDMO Services Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aenova Holding GmbH
  • 19.6. Akums Drugs & Pharmaceuticals Ltd.
  • 19.7. Almac Group Ltd.
  • 19.8. Apeloa Pharmaceutical Co., Ltd.
  • 19.9. Aspen Pharmacare Holdings Ltd.
  • 19.10. Bachem Holding AG
  • 19.11. Cambrex Corporation
  • 19.12. Catalent, Inc.
  • 19.13. CordenPharma International GmbH
  • 19.14. Curia Global, Inc.
  • 19.15. Divi's Laboratories Ltd.
  • 19.16. EuroAPI
  • 19.17. Evonik Industries AG
  • 19.18. Fujifilm Diosynth Biotechnologies
  • 19.19. Hovione Ltd.
  • 19.20. Lonza Group AG
  • 19.21. PCI Pharma Services
  • 19.22. Piramal Pharma Solutions
  • 19.23. Porton Pharma Solutions Ltd.
  • 19.24. Recipharm AB
  • 19.25. Siegfried Holding AG
  • 19.26. Simtra BioPharma Solutions
  • 19.27. Thermo Fisher Scientific Inc.
  • 19.28. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES SMALL MOLECULES CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA SMALL MOLECULES CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ROUTE SCOUTING AND FEASIBILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ROUTE SCOUTING AND FEASIBILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ROUTE SCOUTING AND FEASIBILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SCALE UP AND TECHNOLOGY TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SCALE UP AND TECHNOLOGY TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SCALE UP AND TECHNOLOGY TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY BUILDING BLOCKS AND INTERMEDIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY BUILDING BLOCKS AND INTERMEDIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY BUILDING BLOCKS AND INTERMEDIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REFERENCE STANDARDS AND IMPURITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REFERENCE STANDARDS AND IMPURITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REFERENCE STANDARDS AND IMPURITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY HIGH POTENCY COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY HIGH POTENCY COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY HIGH POTENCY COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CGMP MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CGMP MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CGMP MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CGMP MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY FORMULATION DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY FORMULATION DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRE FORMULATION STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRE FORMULATION STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRE FORMULATION STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SOLID ORAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PARENTERAL FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PARENTERAL FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL AND QUALITY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL AND QUALITY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL AND QUALITY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL AND QUALITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY METHOD DEVELOPMENT AND VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY METHOD DEVELOPMENT AND VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY METHOD DEVELOPMENT AND VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY STABILITY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY STABILITY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY STABILITY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY RELEASE AND IN PROCESS TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY RELEASE AND IN PROCESS TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY RELEASE AND IN PROCESS TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CHARACTERIZATION AND STRUCTURAL ELUCIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CHARACTERIZATION AND STRUCTURAL ELUCIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CHARACTERIZATION AND STRUCTURAL ELUCIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PACKAGING AND FINISHED DOSAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PACKAGING AND FINISHED DOSAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PACKAGING AND FINISHED DOSAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PACKAGING AND FINISHED DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRIMARY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRIMARY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRIMARY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SECONDARY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SECONDARY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SECONDARY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY AND SUPPORT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY AND SUPPORT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY AND SUPPORT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY AND SUPPORT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CMC DOCUMENTATION SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CMC DOCUMENTATION SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CMC DOCUMENTATION SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY FILING SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY FILING SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY FILING SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY VALIDATION AND QUALIFICATION SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY VALIDATION AND QUALIFICATION SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY VALIDATION AND QUALIFICATION SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY NEW CHEMICAL ENTITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GENERIC APIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GENERIC APIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GENERIC APIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY HIGHLY POTENT APIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY HIGHLY POTENT APIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY HIGHLY POTENT APIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CONTROLLED SUBSTANCES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CONTROLLED SUBSTANCES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CONTROLLED SUBSTANCES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ADVANCED INTERMEDIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ADVANCED INTERMEDIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ADVANCED INTERMEDIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ADVANCED INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY EARLY INTERMEDIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY EARLY INTERMEDIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY EARLY INTERMEDIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LATE STAGE INTERMEDIATES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LATE STAGE INTERMEDIATES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LATE STAGE INTERMEDIATES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY KEY STARTING MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY KEY STARTING MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY KEY STARTING MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY IMPURITIES AND REFERENCE STANDARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY IMPURITIES AND REFERENCE STANDARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY IMPURITIES AND REFERENCE STANDARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY IMPURITIES AND REFERENCE STANDARDS, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS IMPURITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS IMPURITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS IMPURITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DEGRADATION PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DEGRADATION PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DEGRADATION PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL REFERENCE STANDARDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL REFERENCE STANDARDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL REFERENCE STANDARDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DISCOVERY AND EARLY DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DISCOVERY AND EARLY DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DISCOVERY AND EARLY DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGISTRATION AND VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGISTRATION AND VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGISTRATION AND VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LABORATORY SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LABORATORY SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LABORATORY SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SMALL VOLUME COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SMALL VOLUME COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SMALL VOLUME COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LARGE VOLUME COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LARGE VOLUME COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LARGE VOLUME COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY METABOLIC AND ENDOCRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY AUTOIMMUNE AND INFLAMMATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DERMATOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DERMATOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY MID SIZE PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY MID SIZE PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY MID SIZE PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SMALL AND EMERGING PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SMALL AND EMERGING PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SMALL AND EMERGING PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY GENERIC DRUG MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY VIRTUAL AND SPECIALTY PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY VIRTUAL AND SPECIALTY PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY VIRTUAL AND SPECIALTY PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 232. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 234. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 235. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CGMP MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 236. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 237. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL AND QUALITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 238. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PACKAGING AND FINISHED DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 239. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY AND SUPPORT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 240. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, 2018-2032 (USD MILLION)
  • TABLE 242. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ADVANCED INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 243. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY IMPURITIES AND REFERENCE STANDARDS, 2018-2032 (USD MILLION)
  • TABLE 244. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 245. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 246. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 247. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 248. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 249. AMERICAS SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 254. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CGMP MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY FORMULATION DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 256. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ANALYTICAL AND QUALITY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PACKAGING AND FINISHED DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 258. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY REGULATORY AND SUPPORT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, 2018-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY ADVANCED INTERMEDIATES, 2018-2032 (USD MILLION)
  • TABLE 262. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY IMPURITIES AND REFERENCE STANDARDS, 2018-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 264. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 266. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, 2018-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 268. NORTH AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. LATIN AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 272. LATIN AMERICA SMALL MOLECULES CDMO SERVICES MARKET SIZE, BY CUSTOM SYNTHESIS, 2018-2032 (